Skip to main content

Advertisement

Table 1 Baseline demographic and clinical characteristics stratified by 12 week and 24 week duration (n = 93)

From: Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

Characteristic, n (%) Overall (n = 93) 12 week (n = 61) 24 week (n = 26)
Age, median (25%, 75%) 41 (35–49) 41 (34–49) 40 (35–48)
Male sex, n (%) 77 (83) 49 (80) 23 (88)
Drug use in the last 6 months (injecting/non-injecting) 77 (83) 48 (79) 25 (96)
Injecting drug use in the last month 55 (59) 39 (64) 15 (58)
 Heroin 33 (35) 23 (37) 10 (38)
 Cocaine 10 (11) 7 (11) 3 (12)
 Amphetamines 14 (15) 7 (11) 6 (23)
 Other opiates 11 (12) 8 (13) 3 (12)
 Benzodiazapines 2 (2) 2 (3) 0 (0)
Injecting drug use frequency in the last month
 Never 38 (41) 22 (36) 11 (42)
  < daily 40 (43) 29 (48) 10 (38)
  > daily 15 (16) 10 (16) 5 (19)
Opioid substitution treatment (ever) 82 (88) 56 (92) 21 (81)
OST and recent injecting (past month) at enrolment
 No OST, recent injecting 30 (32) 20 (33) 9 (33)
 OST, no recent injecting 23 (25) 15 (25) 5 (19)
 OST, recent injecting 40 (43) 26 (43) 12 (44)
OST and recent injecting (past month) at baseline
 No OST, recent injecting 21 (23) 14 (23) 6 (23)
 OST, no recent injecting 34 (37) 21 (34) 8 (31)
 OST, recent injecting 38 (41) 26 (43) 12 (46)
Stage of liver disease
 No or mild fibrosis (F0-F1) 63 (68) 44 (72) 16 (62)
 Moderate or advanced fibrosis (F2-F3) 20 (22) 12 (20) 5 (19)
 Cirrhosis (F4) 10 (11) 5 (8) 5 (19)
Study site distribution
 Europe 38 (41) 24 (39) 13 (50)
 Australia 40 (43) 27 (44) 9 (35)
 Canada 15 (16) 10 (16) 4 (15)